GovChime
AWARDDEFINITIVE CONTRACTSmall business

Definitive contract HHSO100201100037CNEUMEDICINES INC.

Overview

Award facts

Net obligations
$51.00M
$50,997,157of $216.59M potential value
Period of performance
Sep 15, 2011 to Sep 30, 2018
Ended
Modifications
20
Latest action Aug 4, 2026
Contract type
Definitive contract
PIID HHSO100201100037C

Description of requirement

ADVANCEMENT OF HEMAMAX TOWARDS BLA SUBMISSION FOR THE MITIGATION OF HSARS UNDER THE FDA ANIMAL RULE

Dates and value

Award date
Signed on Sep 15, 2011
Current value
$54,163,469Base and exercised options
Potential value (if all options are exercised)
$216,588,069

Obligations by fiscal year of action

  • FY2026: -$44,403 (de-obligation)
  • FY2018: -$79,193 (de-obligation)
  • FY2017: $187,711
  • FY2016: $5,981,323
  • FY2014: $13,999,818
  • FY2013: $8,309,760
  • FY2012: $8,834,141
  • FY2011: $13,808,000

Total across 8 fiscal years: $50,997,157

Net de-obligation in that fiscal year (obligations withdrawn).

Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Aug 4, 2026. View on USAspending · Recipient on SAM.gov

Recipient

LocationPASADENA, CA
UEICCJ6LS8WE2A6
CAGE code47KZ7
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyNEUMEDICINES INC.

Business types and certifications

Women-ownedFor-profit organizationCorporation (not tax-exempt)

As represented in SAM.gov at the time of the action.

Subcontracting network

The prime, the subcontractors on this award, and their own subcontractors.

Subaward amounts are self-reported by prime contractors to SAM.gov and appear 1 to 2 months after the work. Duplicates are removed on a best-effort basis. Totals are incomplete and not an audit. Source: USAspending.

Agency and place

Awarding and funding

Funded by
  1. Department of Health and Human Services
  2. Administration For Strategic Preparedness And Response
  3. BARDA - ASPR / DAAPPO / BARDA DCMA
Funded from
075-0140Federal accounts (agency financial reports)

Place of performance

Place of performance
Pasadena, Los Angeles County, California 91107-7342
Congressional district (place of performance)
CA-28As reported at the time of the action

Classification and competition

Classification

Product or service (PSC)
6505DRUGS AND BIOLOGICALS (product)

Competition

Extent competed
Full and open competitionA
Solicitation procedures
Negotiated proposal/quoteNP
Set-aside
No set-aside used
Contract pricing
Cost plus fixed feeU
Offers received
20

Contract details

Subcontracting plan
Plan not requiredB
Major program
Advancement of hemamax towards bla submission for the mitigation of hsars under the fda animal rule
Cost Accounting Standards clause
Yes - CAS clause includedY
Certified cost or pricing data
Yes
Service Contract Act labor standards
Yes
Commercial procedures
Commercial item procedures not usedD
Government-furnished property
Transaction does not use GFE/GFPN
Bundled requirement
Not a bundled requirementD
Consolidated requirement
No
Undefinitized action (terms not final)
No
Multi-year contract
No

Linked notices

Notice
Notice ID
Type
Link
Posted

Transaction history

Modification history

Base award
Sep 15, 2011Base obligation at award: $13,808,000
Latest action
Aug 4, 2026 — CloseoutModification P00020; obligation change -$44,403; administrative: no change in scope or value
Latest substantive action
Jan 28, 2016 — Supplemental agreement (within scope)Modification 14
Latest funding action
Sep 20, 2018 — Funding onlyModification 19; obligation change -$79,193; funding only: changes obligations, not scope
Actions by type
  • Base award1
  • Other administrative action8
  • Supplemental agreement (within scope)5
  • Funding only3
  • Option exercised3
  • Closeout1
21 actions recorded, Sep 15, 2011 to Aug 4, 2026; each action counted once.

Similar awards

PIID
Match
Awardee

All contract data

All contract data

Every other field reported for this award, as of its latest reported action

Competition

Evaluation preference
No preference used
Local area set-aside
No
Synopsized publicly (SAM.gov / FedBizOpps)
Yes
Simplified procedures for commercial items
No
A-76 (FAIR Act) action
No

Pricing and financing

Paid by purchase card
No
Latest action: change in base and exercised options
-$44,403
Latest action: change in base and all options
-$44,403

Socio-economic and policy

Recovered materials and sustainability
No clauses included and no sustainability includedC
EPA-designated product
Not requiredE
Clinger-Cohen Act planning (IT)
No

Place and origin

Domestic or foreign entity
U.S. owned businessA
Country of product or service origin
United statesUSA
Place of manufacture
Mfg in U.S.D

Structure

Award or IDV
Award
Award type
Definitive contractD
Awarding agency code
7500
Awarding sub-tier code
7505
Contracting office code
75A501
Transactions recorded under this award key
21

Funding

Funding agency code
7500
Funding sub-tier code
7505
Funding office code
75A501
Treasury accounts
  • 075-2010/2013-0140-000
  • 075-2014/2015-0140-000
  • 075-2017/2018-0140-000
Object classes
  • 25.1: Advisory and assistance services
  • 25.5: Research and development contracts